Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.
To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Platelet activating factor
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).
Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).
Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Moon DG et al. | Platelet modulation of neutrophil superoxide anion production. | 1990 | Thromb. Haemost. | pmid:2160133 |
Page CP et al. | An in vivo model for studying platelet aggregation and disaggregation. | 1982 | Thromb. Haemost. | pmid:7051409 |
Tranquille N and Emeis JJ | The role of cyclic nucleotides in the release of tissue-type plasminogen activator and von Willebrand factor. | 1993 | Thromb. Haemost. | pmid:8097063 |
Wal F et al. | PAF-acether may not mediate the third pathway of platelet aggregation since self-desensitization reduces the effects of low thrombin but enhances those of convulxin. | 1985 | Thromb. Haemost. | pmid:3992525 |
Selak MA | Neutrophil elastase potentiates cathepsin G-induced platelet activation. | 1992 | Thromb. Haemost. | pmid:1333649 |
Sirolli V et al. | Platelet activation and platelet-erythrocyte aggregates in end-stage renal disease patients on hemodialysis. | 2001 | Thromb. Haemost. | pmid:11583316 |
Hornby EJ and Perry CR | 1-O-hexadecyl-2-acetyl-sn-3-glycerophosphorylcholine (PAF): some effects on the aggregation of human platelets by thrombin or collagen. | 1983 | Thromb. Haemost. | pmid:6636035 |
Handley DA et al. | Evidence for a direct effect on vascular permeability of platelet-activating factor induced hemoconcentration in the guinea pig. | 1985 | Thromb. Haemost. | pmid:4089809 |
Cargill DI et al. | Aggregation, release and desensitization induced in platelets from five species by platelet activating factor (PAF). | 1983 | Thromb. Haemost. | pmid:6879508 |
Ward JR et al. | Agonists of toll-like receptor (TLR)2 and TLR4 are unable to modulate platelet activation by adenosine diphosphate and platelet activating factor. | 2005 | Thromb. Haemost. | pmid:16270639 |
Handley DA et al. | Inhibition of PAF-induced systemic responses in the rat, guinea pig, dog and primate by the receptor antagonist SRI 63-441. | 1986 | Thromb. Haemost. | pmid:3775689 |
Ou MC et al. | Potential etiologic role of PAF in two major septic complications; disseminated intravascular coagulation and multiple organ failure. | 1994 | Thromb. Res. | pmid:8191415 |
Bochkov VN et al. | LDL- and agonist-induced Ca(2+)-mobilization in platelets of healthy subjects and in patients with familial hyperlipoproteinemia type II. | 1991 | Thromb. Res. | pmid:2063348 |
Bush LR and Smith SG | Antagonism of U46619-induced aggregation of human and canine platelets by four TXA2 receptor antagonists. | 1986 | Thromb. Res. | pmid:2948294 |
Filep JG et al. | C-reactive protein inhibits binding of platelet-activating factor to human platelets. | 1991 | Thromb. Res. | pmid:2063349 |
Belch JJ et al. | Whole blood white cell aggregation: a novel technique. | 1987 | Thromb. Res. | pmid:2448894 |
Sturk A et al. | Synergistic effects of platelet-activating factor and other platelet agonists in human platelet aggregation and release: the role of ADP and products of the cyclooxygenase pathway. | 1985 | Thromb. Res. | pmid:2934863 |
Namm DH et al. | Species specificity of the platelet responses to 1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine. | 1982 | Thromb. Res. | pmid:7071810 |
Brown JE and Thuy LP | The binding of bovine platelet aggregating factor to human platelets. | 1981 Apr 1-15 | Thromb. Res. | pmid:7292446 |
Ishii H et al. | Thiolprotease inhibitor, EST, can inhibit thrombin-induced platelet activation. | 1990 | Thromb. Res. | pmid:2382255 |
Tokumura A et al. | Platelet aggregation induced by ether-linked phospholipids. 1. Inhibitory actions of bovine serum albumin and structural analogues of platelet activating factor. | 1987 | Thromb. Res. | pmid:3647677 |
Hofmann B et al. | Proaggregatory and inhibitory effects of 2-O-ethyl analogues of platelet-activating factor (PAF) on human and rabbit platelets. | 1988 | Thromb. Res. | pmid:3381200 |
Davis RB and Johnson MF | Effects of bacterial endotoxin and platelet activating factor (PAF) on human platelet aggregation in native whole blood. | 1986 | Thromb. Res. | pmid:3544327 |
Glusa E et al. | Verapamil is a potent inhibitor of 5-HT-induced platelet aggregation. | 1989 | Thromb. Res. | pmid:2528843 |
Stahl GL et al. | Protective effects of a specific platelet activating factor (PAF) antagonist, WEB 2086, in traumatic shock. | 1989 | Thromb. Res. | pmid:2718150 |
Sloan IG and Firkin BG | Impaired fibrinolysis in patients with thrombotic or haemostatic defects. | 1989 | Thromb. Res. | pmid:2814943 |
Skeaff CM and Holub BJ | The effect of fish oil consumption on platelet aggregation responses in washed human platelet suspensions. | 1988 | Thromb. Res. | pmid:3187952 |
Griffin KJ and Levy JV | The thieno-triazolodiazepine WEB 2086 inhibits platelet aggregation and ATP release from porcine platelets induced by platelet activating factor (PAF). | 1988 | Thromb. Res. | pmid:3187959 |
Beaumont DO et al. | Measuring platelet function with platelet shape change, an early event in aggregation. | 1989 | Thromb. Res. | pmid:2646752 |
Janero DR et al. | Specific binding of 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor) to the intact canine platelet. | 1988 | Thromb. Res. | pmid:3413730 |
Suttorp N et al. | Stimulation of PAF-synthesis in pulmonary artery endothelial cells by Staphylococcus aureus alpha-toxin. | 1992 | Thromb. Res. | pmid:1440526 |
Benveniste J et al. | Biosynthesis of platelet-activating factor (PAF-ACETHER). II. Involvement of phospholipase A2 in the formation of PAF-ACETHER and lyso-PAF-ACETHER from rabbit platelets. | 1982 | Thromb. Res. | pmid:6803388 |
Seth P et al. | Effect of platelet activating factor antagonists in different models of thrombosis. | 1994 | Thromb. Res. | pmid:7900097 |
Klöcking HP et al. | Release of tissue-type plasminogen activator by platelet-activating factor. | 1985 | Thromb. Res. | pmid:4040278 |
Nunn B | Total and selective desensitisation of human platelets to synthetic platelet activating factor (PAF): evidence that extracellular PAF does not mediate collagen-induced aggregation. | 1983 | Thromb. Res. | pmid:6648898 |
Teng CM et al. | Antiplatelet actions of some coumarin compounds isolated from plant sources. | 1992 | Thromb. Res. | pmid:1523611 |
Chlopicki S et al. | Obligatory role of lipid mediators in platelet-neutrophil adhesion. | 2003 | Thromb. Res. | pmid:14592550 |
Kawamura M et al. | Inhibitory effect of TCV-309, a novel platelet activating factor (PAF) antagonist, on endotoxin-induced disseminated intravascular coagulation in rats: possible role of PAF in tissue factor generation. | 1993 | Thromb. Res. | pmid:8332959 |
Stormorken H et al. | A new bleeding disorder: lack of platelet aggregatory response to adrenaline and lack of secondary aggregation to ADP and platelet activating factor (PAF). | 1983 | Thromb. Res. | pmid:6857589 |
Kloprogge E et al. | Stimulus-response coupling in human platelets. Evidence against a role of PAF-acether in the "third pathway'. | 1983 | Thromb. Res. | pmid:6857605 |
Joseph R et al. | Endothelin-1 and human platelet activity. | 1991 | Thromb. Res. | pmid:2028454 |
Tencé M et al. | Ether-phospholipid composition in neutrophils and platelets. | 1985 | Thromb. Res. | pmid:4024039 |
Hayashi M et al. | Detection of platelet-activating factor in exudates of rats with phorbol myristate acetate-induced pleurisy. | 1987 | Thromb. Res. | pmid:3433255 |
Ding YA et al. | Antiplatelet actions of 2-(4-[1-(2-chlorophenyl) piperazinyl]) methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one compound. | 1995 | Thromb. Res. | pmid:7740521 |
Bussolino F et al. | Intravascular release of platelet activating factor in children with sepsis. | 1987 | Thromb. Res. | pmid:3441909 |
Ostermann G et al. | Stimulation and desensitization of human and rabbit platelets by 1-O-hexadecyl-2-O-methyl-rac-glycero-3-phosphocholine and analogues. | 1986 | Thromb. Res. | pmid:3764811 |
Pfliegler G et al. | Sodium fluoride induced activation of phospholipase C in intact human platelets does not depend on ADP, PAF or arachidonate products. | 1993 | Thromb. Res. | pmid:8503122 |
Altman R et al. | Why single daily dose of aspirin may not prevent platelet aggregation. | 1988 | Thromb. Res. | pmid:3140408 |
McGowan EB and Detwiler TC | Characterization of the thrombin-induced desensitization of platelet activation by thrombin. | 1983 | Thromb. Res. | pmid:6356458 |
Kinlough-Rathbone RL et al. | Effects of cathepsin G pretreatment of platelets on their subsequent responses to aggregating agents. | 1999 | Thromb. Res. | pmid:10527409 |